21 Mar 2016 15:45
SalvaRx the latest cancer drug firm seeking AIM admission
(ShareCast News) - London's AIM could soon see another biotechnology company among its constituents, with the announcement on Monday that SalvaRx was seeking admission to trading following the reverse takeover of 3Legs Resources. SalvaRx, through its ownership of iOx Therapeutics, said it was curren
Read more